相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
Tamara Dangouloff et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
Paul Gissen et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
Alessandra Blonda et al.
FRONTIERS IN PHARMACOLOGY (2021)
Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
Khadidja Abdallah et al.
FRONTIERS IN PHARMACOLOGY (2021)
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database
Stephanie Nguengang Wakap et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
AAN position statement: Ethical issues in clinical research in neurology
Benjamin Tolchin et al.
NEUROLOGY (2020)
Principles for deliberative processes in health technology assessment
Kenneth Bond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)
Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy
Ali Jalali et al.
JOURNAL OF PEDIATRICS (2020)
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Praveen Thokala et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2020)
A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy
Erik Landfeldt et al.
ACTA PAEDIATRICA (2019)
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
Santiago Zuluaga-Sanchez et al.
PHARMACOECONOMICS (2019)
Adjusting for Inflation and Currency Changes Within Health Economic Studies
Hugo C. Turner et al.
VALUE IN HEALTH (2019)
ANALYSIS OF DUPLICATION AND TIMING OF HEALTH TECHNOLOGY ASSESSMENTS ON MEDICAL DEVICES IN EUROPE
Katharina Hawlik et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2018)
Economic Modeling Considerations for Rare Diseases
Isobel Pearson et al.
VALUE IN HEALTH (2018)
Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
Sandra Nestler-Parr et al.
VALUE IN HEALTH (2018)
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
Ting Wang et al.
VALUE IN HEALTH (2018)
Nusinersen for Spinal Muscular Atrophy Are We Paying Too Much for Too Little?
Vinay Prasad
JAMA PEDIATRICS (2018)
Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy
Alyssa M. Burgart et al.
JAMA PEDIATRICS (2018)
Stakeholder participation on the path to universal health coverage: the use of evidence-informed deliberative processes
Rob Baltussen et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2018)
New treatments for serious conditions: ethical implications
N. M. P. King et al.
GENE THERAPY (2017)
Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain
Julio Lopez-Bastida et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review
Ingrid E. C. Verhaart et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
C. Schey et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries
Elena Nicod et al.
VALUE IN HEALTH (2017)
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries
Elena Nicod
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2017)
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
Manon Hache et al.
JOURNAL OF CHILD NEUROLOGY (2016)
Disease burden of spinal muscular atrophy in Germany
Constanze Klug et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?
Stephen Maxwell Montgomery et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment
Liesbet van de Wetering et al.
PHARMACOECONOMICS (2015)
Spinal Muscular Atrophy: Therapeutic Strategies
Diana Castro et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2014)
The level of agreement between child self-reports and parent proxy-reports of health-related quality of life in boys with Duchenne muscular dystrophy
Yoonjeong Lim et al.
QUALITY OF LIFE RESEARCH (2014)
Clinical Trials in Rare Disease: Challenges and Opportunities
Erika F. Augustine et al.
JOURNAL OF CHILD NEUROLOGY (2013)
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Thomas Morel et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall
E. J. van de Wetering et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
Wim Pinxten et al.
JOURNAL OF MEDICAL ETHICS (2012)
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Wills Hughes-Wilson et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand
Sitaporn Youngkong et al.
HEALTH RESEARCH POLICY AND SYSTEMS (2012)
Pricing and reimbursement of orphan drugs: the need for more transparency
Steven Simoens
ORPHANET JOURNAL OF RARE DISEASES (2011)
Challenges in Health State Valuation in Paediatric Economic Evaluation Are QALYs Contraindicated?
Wendy J. Ungar
PHARMACOECONOMICS (2011)
Current Challenges and Future Research in Measuring Preferences for Pediatric Health Outcomes
Lisa A. Prosser
JOURNAL OF PEDIATRICS (2009)
Assessing the economic challenges posed by orphan drugs
Michael F. Drummond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2007)
Consensus statement for Standard of Care in Spinal Muscular Atrophy
Ching H. Wang et al.
JOURNAL OF CHILD NEUROLOGY (2007)
Assessment of health-related quality of life in children: A review of conceptual, methodological, and regulatory issues
LS Matza et al.
VALUE IN HEALTH (2004)
Can parents rate their child's health-related quality of life? Results of a systematic review
C Eiser et al.
QUALITY OF LIFE RESEARCH (2001)
分享论文
